echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > UK cell and gene clinical trials up 45% from 2018

    UK cell and gene clinical trials up 45% from 2018

    • Last Update: 2021-03-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    cell and gene therapy Catapult revealed that there are currently 127 ongoing cell and gene trials in the UK, an increase of about 45% compared to 2018, accounting for 12% of the total number of clinical studies on cell and gene therapy worldwide.

    Last year's Catapult report from Cell and Gene Therapy also documented an increase in employment in the sector, showing that the industry currently supports more than 3,000 jobs, including 1,700 in manufacturing and bio-processing.

    In addition, the report shows that the UK will more than double the number of jobs in its cells and genes by 2024 as more and more therapies move towards commercialisation. Over the past seven years, the industry has expanded from 500 jobs in 2012 to more than 3,000, and is expected to reach 6,000 by 2024.

    Now, the organisation's 2019 UK Advanced Therapeutics Clinical Trials Database has shown that 77 per cent of cell and gene therapy trials in the UK are sponsored by commercial organisations, compared with just 25 per cent in 2013, reflecting the company's continued investment in cells and genes.

    Encouraging figures suggest that the NHS and the UK ecosystem are providing the right platform for more and more innovative therapies to be put into clinical practice.

    Health Secretary Nicola Blackwood commented that the "extraordinary figures" showed life sciences in the UK were rapidly leading the way in providing cutting-edge treatment for NHS patients.

    She added: "Our research capabilities continue to grow and our excellence in the NHS as a whole not only allows patients to get more innovative drugs, but also invests in companies that seek outstanding expertise." ”(

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.